8-K: Adicet Bio Receives FDA Clearance for ADI-270 IND Application in Renal Cell Carcinoma

Adicet Bio has received FDA clearance for its Investigational New Drug application for ADI-270, a novel CAR T-cell therapy, to treat relapsed/refractory renal cell carcinoma.

Summary

• Adicet Bio announced that the FDA has cleared its Investigational New Drug (IND) application for ADI-270.
• ADI-270 is an armored allogeneic off-the-shelf gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD70+ cancers.
• The therapy is intended for the treatment of relapsed/refractory renal cell carcinoma (RCC).
• A Phase 1 clinical trial is planned to start in the second half of 2024 to assess the safety and anti-tumor activity of ADI-270.
• Preliminary clinical data from the trial is expected in the first half of 2025.
• The trial will investigate ADI-270 as a monotherapy in adults with relapsed or refractory clear cell RCC.
• Patients will receive a single dose of ADI-270 with a starting dose of 3E8 CAR+ cells, and may be eligible for a second dose.
• The trial will evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity, including overall response rate, duration of response, and disease control rate.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA clearance and the initiation of a clinical trial for a novel therapy. The language is optimistic about the potential of ADI-270, but also acknowledges the inherent risks in drug development.

Positives

• FDA clearance of the IND application is a significant milestone for Adicet Bio.
• ADI-270 is a novel therapy with a unique mechanism of action targeting CD70+ cancers.
• The therapy has the potential to address the unmet need for effective treatments for relapsed/refractory renal cell carcinoma.
• The Phase 1 trial will provide valuable data on the safety and efficacy of ADI-270.
• The trial design includes dose escalation and expansion phases to optimize treatment.

Risks

• The success of the clinical trial is not guaranteed, and results may not meet expectations.
• Regulatory approval processes are lengthy and unpredictable.
• The company's ability to raise additional capital could be impacted by global events.
• There are risks associated with the development of novel therapies, including potential safety issues.
• The company's preclinical and clinical studies could be disrupted by global geopolitical conflicts, economic conditions and public health emergencies.

Future Outlook

The company plans to initiate a Phase 1 clinical trial in the second half of 2024 and expects to share preliminary clinical data in the first half of 2025. The company believes ADI-270 has the potential to become an important therapeutic option for patients with RCC and other CD70+ tumors.

Management Comments

• Chen Schor, President and Chief Executive Officer of Adicet Bio, stated that ADI-270 is the first ever gamma delta 1 CAR T cell therapy candidate to enter clinical trials for the treatment of solid tumors.
• Chen Schor also noted that the FDA's clearance of the IND application is a significant achievement for Adicet.

Industry Context

This announcement is significant as it marks the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors, representing a novel approach in cancer treatment. The focus on renal cell carcinoma, a disease with limited treatment options, highlights the potential impact of this therapy.

Comparison to Industry Standards

• The development of ADI-270 as an allogeneic off-the-shelf CAR T-cell therapy distinguishes it from autologous CAR T-cell therapies like those from Gilead (Yescarta) and Novartis (Kymriah), which require patient-specific cell processing.
• Unlike traditional CAR T-cell therapies that target B-cell malignancies, ADI-270 targets CD70+ solid tumors, a different approach than companies like Kite Pharma (Gilead) and Juno Therapeutics (acquired by Celgene/Bristol Myers Squibb).
• The use of gamma delta T cells is a novel approach compared to the more common alpha-beta T cells used in other CAR T-cell therapies, potentially offering unique advantages in terms of safety and efficacy.
• The 'armored' design of ADI-270, incorporating a dominant negative form of the Transforming growth factorreceptor II (dnTGFRII), aims to overcome the immunosuppressive tumor microenvironment, a challenge faced by many other cancer therapies.

Stakeholder Impact

• Shareholders may react positively to the news of FDA clearance and the initiation of a clinical trial.
• Patients with relapsed/refractory renal cell carcinoma may benefit from a new treatment option.
• Employees of Adicet Bio will be involved in the clinical trial and further development of ADI-270.
• The company's suppliers and partners may see increased activity related to the clinical trial.

Next Steps

• Initiate a Phase 1 clinical trial in the second half of 2024.
• Enroll patients with relapsed or refractory clear cell RCC in the trial.
• Evaluate the safety, tolerability, and anti-tumor activity of ADI-270.
• Share preliminary clinical data in the first half of 2025.

Key Dates

Keywords

ADI-270, CAR T-cell therapy, Renal Cell Carcinoma, FDA, IND application, Gamma delta T cells, CD70, Clinical Trial, Oncology, Biotechnology